ArticlemBio2018
Rational Design of Biosafety Level 2-Approved, Multidrug-Resistant Strains of Mycobacterium tuberculosis through Nutrient Auxotrophy.
Open access · goldAbstract read
In one paragraph
Article in mBio, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 54 citations in OpenAlex.
- Polyketide synthase 12 is anbioRxiv : the preprint server for biology · 2026Article
- What goes around comes around: updates in the study ofInfection and immunity · 2026Review
- Identification of chemical features for improved outer membrane permeation in mycobacteria using machine learning.Nature microbiology · 2026Article
- Applications of synthetic biology in biomedicine.Molecular biomedicine · 2026Review
- Antimicrobial peptides for tuberculosis in a post-antibiotic era: from in vitro promise to therapeutic potential.npj antimicrobials and resistance · 2026Review
- A single mycobacterial ligand organizes multi-receptor signaling to reprogram macrophage lipid metabolism.bioRxiv : the preprint server for biology · 2026Article
- 3-(Pyridine-3-ylmethylene)chroman-4-one and tetralone derivatives: synthesis,RSC medicinal chemistry · 2026Article
- Tre-DST: A Drug Susceptibility Test forACS infectious diseases · 2026Article
- Mycobacteria trehalose dimycolate interactions with host Mincle remodel blood-brain barrier junctions for brain invasion.Cell reports · 2025Article
- Structural isomerisation affects the antitubercular activity of adamantyl-isoxyl adducts.Journal of enzyme inhibition and medicinal chemistry · 2025Article
- Mapping unsolved lipidomes accelerates lipid discovery in major bacterial pathogens.bioRxiv : the preprint server for biology · 2025Article
- Structural and functional analysis of theProceedings of the National Academy of Sciences of the United States of America · 2025Article
- Vitamin C potentiates the killing ofmBio · 2025Article
- The Parkinson's drug benztropine possesses histamine receptor 1-dependent host-directed antimicrobial activity against Mycobacterium tuberculosis.npj antimicrobials and resistance · 2025Article
- Knockout of the Agrobacterium ILVC gene generates a valine-isoleucine auxotrophic strain for plant transformation.Transgenic research · 2025Article
- Engineered Mycobacteriophage TM4::GeNL Rapidly Determines Bedaquiline, Pretomanid, Linezolid, Rifampicin, and Clofazimine Sensitivity in Mycobacterium tuberculosis Clinical Isolates.The Journal of infectious diseases · 2025Article
- Xpert MTB/RIF Ultra enables sensitive detection ofThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2024Article
- Catalase activity deficiency sensitizes multidrug-resistant Mycobacterium tuberculosis to the ATP synthase inhibitor bedaquiline.Nature communications · 2024Article
- Antibacterial efficacy of mycobacteriophages against virulent Mycobacterium tuberculosis.BMC microbiology · 2024Article
- Discovery of potent antimycobacterial agents targeting lumazine synthase (RibH) of Mycobacterium tuberculosis.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Catherine VilchèzeHoward Hughes Medical Institute, Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Jacqueline CopelandHoward Hughes Medical Institute, Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Tracy L KeiserHoward Hughes Medical Institute, Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Torin WeisbrodHoward Hughes Medical Institute, Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Jacqueline WashingtonDepartment of Biology and Chemistry, Nyack College, Nyack, New York, USA.
Paras JainHoward Hughes Medical Institute, Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Adel MalekHoward Hughes Medical Institute, Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Brian WeinrickHoward Hughes Medical Institute, Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
William R JacobsHoward Hughes Medical Institute, Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA jacobsw@hhmi.org.
Albert Einstein College of Medicine · USHoward Hughes Medical Institute · USNyack College · US
Funding
WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI STEVEN C. ALMO · 1985 to 2026
$111.2MValidation and Application of a Model for Human-like TB Latency in RabbitsU19AI111276 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI ALLAND, DAVID, ALLAND, DAVID · 2014 to 2020
$23.3MMolecular Genetic Analysis of Mycobacterium TuberculosisR37AI026170 · NIAID · ALBERT EINSTEIN COL OF MED YESHIVA UNIV · PI WILLIAM Robert JACOBS · 2004 to 2026
$7.7MMOLECULAR GENETIC ANALYSIS OF MYCOBACTERIUM TUBERCULOSISR01AI026170 · NIAID · YESHIVA UNIVERSITY · PI JACOBS, WILLIAM ROBERT · 1989 to 2022
$7.1MVaccines for Extensively Drug Resistant TuberculosisR01AI098925 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI JACOBS, WILLIAM ROBERT · 2012 to 2016
$5.8MGeneration of a Complete Set of Precise Null Bar-Coded Deletion Mutants of Mycobacterium tuberculosisR24AI134650 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Shazia Hamid, WILLIAM Robert JACOBS · 2017 to 2026
$5.6MGeographic Medicine and Emerging InfectionsT32AI070117 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI WEISS, LOUIS M. · 2008 to 2023
$5.1MDrugs targeting persistent Mycobacterium TuberculosisR01AI097548 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI JACOBS, WILLIAM ROBERT · 2013 to 2016
$2.6MHoward Hughes Medical InstituteNCI NIH HHS P30 CA013330NIAID NIH HHS R01 AI026170NIAID NIH HHS R01 AI097548NIAID NIH HHS R01 AI098925NIAID NIH HHS R24 AI134650NIAID NIH HHS R37 AI026170NIAID NIH HHS T32 AI070117NIAID NIH HHS U19 AI111276
Abstract
Multidrug-resistant (MDR) tuberculosis, defined as tuberculosis resistant to the two first-line drugs isoniazid and rifampin, poses a serious problem for global tuberculosis control strategies. Lack of a safe and convenient model organism hampers progress in combating the spread of MDR strains of
Indexed as
Drug Resistance, Multiple, BacterialAnimalsAntitubercular AgentsArginineBacterial ProteinsContainment of BiohazardsFemaleHumansIsoniazidMiceMice, Inbred C57BLMice, SCIDMicrobial Sensitivity TestsMutationMycobacterium tuberculosisNutrientsAntitubercular AgentsArginineBacterial ProteinsIsoniazidNutrientsRifampinarginineauxotrophymethioninemultidrug resistanceMycobacterium tuberculosis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.